Parsons James T. - 17 Nov 2021 Form 4 Insider Report for Trillium Therapeutics Inc.

Reporting relationship: Chief Financial Officer
Issuer ticker: N/A
Reported as of: 17 Nov 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Nov 2021, 12:29:14 UTC
Prior SEC filing: 16 Jul 2021
Next SEC filing: 03 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ James Parsons, Attorney-in-Fact

Key filing fact

Parsons James T. filed Form 4 for Trillium Therapeutics Inc. on 19 Nov 2021.

Key facts

This page summarizes Parsons James T.'s Form 4 filing for Trillium Therapeutics Inc..
8 reported transactions and 8 derivative rows are listed below.
Accepted by SEC: 19 Nov 2021, 12:29.

Change

Previous filing in this sequence was filed on 16 Jul 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TRIL transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -180,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 17 Nov 2021
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 180,000
Exercise price: $12.03
Footnotes: F1

TRIL transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -94,792
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 17 Nov 2021
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 94,792
Exercise price: $0.3000
Footnotes: F1, F2

TRIL transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -59,896
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 17 Nov 2021
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 59,896
Exercise price: $3.34
Footnotes: F1, F3

TRIL transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -5,761
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 17 Nov 2021
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 5,761
Exercise price: $7.27
Footnotes: F1, F4

TRIL transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -36,204
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 17 Nov 2021
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 36,204
Exercise price: $8.18
Footnotes: F1, F5

TRIL transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -24,390
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 17 Nov 2021
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 24,390
Exercise price: $9.65
Footnotes: F1, F6

TRIL transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -30,171
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 17 Nov 2021
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 30,171
Exercise price: $11.04
Footnotes: F1, F7

TRIL transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -30,171
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 17 Nov 2021
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 30,171
Exercise price: $15.27
Footnotes: F1, F8

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Parsons James T. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 8 footnotes

Footnote F1

On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.

Footnote F2

The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.

Footnote F3

The exercise price of these options is $4.23 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.

Footnote F4

The exercise price of these options is $9.20 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.

Footnote F5

The exercise price of these options is $10.35 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.

Footnote F6

The exercise price of these options is $12.22 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.

Footnote F7

The exercise price of these options is $13.98 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.

Footnote F8

The exercise price of these options is $19.333 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.